Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 14/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16705687 | 0.87 | BCHE (0.41) | KCNH2SIGMAR1 | |
| SCHEMBL31186159 | 0.78 | BCHE (0.53) | SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL16705656 | 0.78 | BCHE (0.44) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL18121367 | 0.77 | CXCR4 (0.52) | KCNH2 | |
| SCHEMBL465875 | 0.76 | BCHE (0.53) | SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL16705683 | 0.76 | SIGMAR1 (0.44) | KCNH2HRH3SIGMAR1SMN1; SMN2 | |
| SCHEMBL9282338 | 0.75 | ALDH1A1 (0.39) | KCNJ1KCNH2SIGMAR1HTTSMN1; SMN2 | |
| SCHEMBL16728791 | 0.74 | BCHE (0.44) | — | |
| SCHEMBL3320134 | 0.74 | BCHE (0.53) | HRH3HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL31721289 | 0.74 | BCHE (0.53) | HRH3HTTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068787-B1 | PICOLINATE CROSS-BRIDGED CYCLAMS, CHELATES WITH METALLIC CATIONS AND USE THEREOF | UNIVERSITÉ DE BRETAGNE OCCIDENTALE (FR) | 2017-11-01 | — | — | EP | disclosed |
| US-20160287733-A1 | PICOLINATE CROSS-BRIDGED CYCLAMS, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-10-06 | — | — | US | disclosed |
| US-20160287733-A1 | PICOLINATE CROSS-BRIDGED CYCLAMS, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-10-06 | — | — | US | disclosed |
| EP-2871186-B1 | Picolinate cross-bridged cyclams, chelates with metallic cations and use thereof | UNIVERSITÉ DE BRETAGNE OCCIDENTALE (FR) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015071334-A1 | PICOLINATE CROSS-BRIDGED CYCLAMS, CHELATES WITH METALLIC CATIONS AND USE THEREOF | UNIVERSITÉ DE BRETAGNE OCCIDENTALE (FR) | 2015-05-21 | — | — | WO | disclosed |
| EP-2871186-A1 | Picolinate cross-bridged cyclams, chelates with metallic cations and use thereof | Université de Bretagne Occidentale (FR) | 2015-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287733-A1 | PICOLINATE CROSS-BRIDGED CYCLAMS, CHELATES WITH METALLIC CATIONS AND USE THEREOF | SLC39A14, SLC67A1, SLC39A3 | KCNJ1 1960/4885KCNH2 1257/4885HRH3 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.